We’ve pulled together all of the psilocybin-related patents and published patent applications that were filed in the U.S. or that later may be filed in the U.S. and become a U.S. patent (as discussed in further detail here). These start with Albert Hofmann’s Sandoz patents from 1958 and ‘59, and go up through the most recent applications to publish.
It’s important to note that patent applications are kept secret for at least 18 months after filing. So if you came looking for one of the many applications recently announced by a company in the space, your best bet is to check our Psilocybin Patent Filings Tracker. But keep checking back—we’ll update this table whenever new DMT-related applications become public, and we’ll continue to add new tables for other psychedelic compounds (along with our existing MDMA, 5-MeO-DMT, ketamine, LSD, DMT, and ibogaine tables), and post new articles discussing IP in the psychedelics space in the months to come.
Calyx Law provides legal and intellectual property counsel for innovators in life sciences and high tech.
Note: The applications and patents in the table include all U.S. and PCT filings with substantive claims to psilocybin compositions, formulations, and methods of use or production. Applications or patents filed in other jurisdictions, or those where psilocybin is only referenced incidentally, are not included. Where a PCT application has already entered prosecution in the U.S., only the U.S. application is included. “Priority date” refers to the earliest filing date on which an applicant can rely (typically, the filing date of a U.S. provisional application); it is used to determine who filed first and what public information qualifies as prior art.